Strengthening pharma's contract with society: the value of trusted partnerships between pharma and healthcare facilitated by real-world data

Abstract

This White Paper is authored by 11 industry real-world evidence (RWE) experts, with support from IQVIA, as part of the ‘RWE Leadership Forum’: a group of industry leaders who come together as noncompetitive partners to understand and respond to internal or external RWD/E challenges and opportunities with a single expert voice. Herein we aim to clarify the rules of engagement between pharma and healthcare in order to establish trust-based partnerships, which will unlock unique value for society, including the medical community and the ultimate beneficiary, the patient.

Introducing Volume 10 of the Journal of Comparative Effectiveness Research

“…The importance of real-world data is also highlighted in the White Paper from Seewald et al published in issue 3 of 2020 [7]. The paper is authored by 11 industry RWE experts, as part of the 'RWE Leadership Forum': a group of industry leaders aiming to understand and respond to internal or external real-world data/real-world evidence challenges and opportunities.…”

Journal of Comparative Effectiveness Research welcoming the submission of study design protocols to foster transparency and trust in real-world evidence

“…Steps are being made to enable researchers to develop clear and reproducible RWE study protocols, for instance through the recently published HARmonized Protocol Template to Enhance Reproducibility (HARPER), which builds on other templates such as the Structured Template and Reporting Tool for Real World Evidence (STaRT-RWE) [ 6 , 7 ]. Industry are also keen to build trusted partnerships with healthcare providers regarding real-world data [ 8 ].…”